olfactory receptor family 51 subfamily B member 5Genealiases: HOR5'Beta5 · OR11-37
Q-omics provides the consensus-scored OR51B5 profile across patient tissues and cancer cell-line models. OR51B5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, OR51B5 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, OR51B5 RNA expression shows 12,400 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where OR51B5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51B5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51B5 survival associations across molecular data types. OR51B5 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51B5 RNA expression–survival associations across cancer types. High OR51B5 expression shows unfavorable associations in UVM, ACC, COAD and LUAD, but favorable associations in UCS and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for OR51B5 RNA expression.
This table summarizes OR51B5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR51B5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51B5 shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher OR51B5 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p = .010).
This table shows molecular features associated with OR51B5 in patient tissues and cancer cell lines. In patient samples, OR51B5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR51B5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
